One of the most promising treatments for Parkinson’s disease has hit a snag after researchers found evidence that it may make patients worse…The NorthShore study examined 1,098 Parkinson’s patients who had their DNA sequenced at the Mayo Clinic and were then contacted up to 15 years later. Those with a genetic variant that led to the lowest production of alpha-synuclein were 23 percent more likely to develop dementia or need a wheelchair than those whose bodies made more alpha-synuclein.

Bloomberg Businessweek by Michelle Fay Cortez

Tags: alpha synuclein, Bloomberg Businessweek, DNA sequence, genetic variant, Genomics, Neurology, NorthShore, parkinson's disease, Research, setback